{"doi":"10.1016/j.diabres.2011.08.016","title":"Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes","abstract":null,"journal":"Diabetes Research and Clinical Practice","year":2012,"id":591036,"datarank":2.849581457840837,"base_score":3.9889840465642745,"endowment":3.9889840465642745,"self_citation_contribution":0.5983476069846413,"citation_network_contribution":2.2512338508561958,"self_endowment_contribution":0.5983476069846413,"citer_contribution":2.2512338508561958,"corpus_percentile":null,"corpus_rank":null,"citation_count":53,"citer_count":38,"citers_with_citation_signal":32,"citers_with_endowment":32,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1512154,"name":"Yuko Akehi","orcid":null,"position":1,"is_corresponding":false},{"id":1512156,"name":"Hiromasa Takenoshita","orcid":null,"position":2,"is_corresponding":false},{"id":1512157,"name":"Ryoko Nagaishi","orcid":null,"position":3,"is_corresponding":false},{"id":1512158,"name":"Yuichi Terawaki","orcid":null,"position":4,"is_corresponding":false},{"id":1512159,"name":"Hisahiro Nagasako","orcid":null,"position":5,"is_corresponding":false},{"id":1512160,"name":"Tadachika Kudo","orcid":null,"position":6,"is_corresponding":false},{"id":1512161,"name":"Takehiko Kodera","orcid":null,"position":7,"is_corresponding":false},{"id":1512162,"name":"Kunihisa Kobayashi","orcid":null,"position":8,"is_corresponding":false},{"id":1512163,"name":"Hidenori Urata","orcid":null,"position":9,"is_corresponding":false},{"id":347153,"name":"Toshihiko Yanase","orcid":"0000-0002-7135-4434","position":10,"is_corresponding":false},{"id":1512152,"name":"Takashi Nomiyama","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes","abstract":null,"is_dataset_classified":null,"base_score":3.9889840465642745,"endowment":3.9889840465642745,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21899912","pmcid":null,"openalex_id":"https://openalex.org/W2147698512","authors":[],"funders":[],"total_grants":0,"fwci":3.6312,"citation_percentile":0.93586212,"influential_citations":0,"citation_trend":[{"year":2012,"count":5},{"year":2013,"count":7},{"year":2014,"count":8},{"year":2015,"count":11},{"year":2016,"count":3},{"year":2017,"count":5},{"year":2018,"count":2},{"year":2019,"count":5},{"year":2020,"count":3},{"year":2021,"count":1},{"year":2022,"count":2},{"year":2023,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S016882271100461X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S016882271100461X?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.diabres.2011.08.016","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21899912","host_type":"repository"}],"fields_of_study":["Diabetes Treatment and Management","Peptidase Inhibition and Analysis","Antiplatelet Therapy and Cardiovascular Diseases","Adult","Aged","Asia","Asian People","Biomarkers","Body Mass Index","Diabetes Mellitus, Type 2","Diabetic Nephropathies","Dipeptidyl-Peptidase IV Inhibitors","Female","Glycated Hemoglobin","Humans","Male","Middle Aged","Pyrazines","Sitagliptin Phosphate","Treatment Outcome","Triazoles"],"mesh_terms":["Sitagliptin Phosphate","Adult","Aged","Asia","Diabetes Mellitus, Type 2","Diabetic Nephropathies","Female","Glycated Hemoglobin","Humans","Male","Middle Aged","Pyrazines","Triazoles","Biomarkers","Body Mass Index","Treatment Outcome","Asian People","Dipeptidyl-Peptidase IV Inhibitors"],"keywords":["Sitagliptin","Medicine","Dipeptidyl peptidase-4 inhibitor","Dipeptidyl peptidase-4","Type 2 diabetes","Sitagliptin Phosphate","Diabetes mellitus","Internal medicine","Pharmacology","Endocrinology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-25T13:53:31.649160Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}